Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease

BACKGROUND: Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80–90% of metastatic breast cancers providing support for blockade of AR-signalling. However, clini...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Simigdala, Nikiana, Pancholi, Sunil, Ribas, Ricardo, Folkerd, Elizabeth, Liccardi, Gianmaria, Nikitorowicz-Buniak, Joanna, Johnston, Stephen R., Dowsett, Mitch, Martin, Lesley-Ann
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6068155/
https://ncbi.nlm.nih.gov/pubmed/29991699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0158-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares